Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Mesoblast Limited — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.41 (market cap $28.50B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is far larger — about 16.3× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 37,320,110). Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days and Mesoblast Limited for 15 Days on average.
| LQD | MESO | |
|---|---|---|
Market Cap | $28.50B | $1.75B |
Volume | 37,320,110 | 239,027 |
Sector | Fixed Income | Health |
52-Week High | $112.91 | $20.96 |
52-Week Low | $101.83 | $13.19 |
Typical Hold Time | 125 Days | 15 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $102.47 with a slight 0.34% daily gain amid a challenging bond market environment. The ETF shows bearish technical signals with moving averages indicating selling pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September and concerns about investment-grade corporate bonds as Treasury yields reach multi-decade highs.
The outlook remains cautious given the bearish technical setup and rising bond yields pressuring corporate debt valuations. Key risks include continued bond market volatility and higher borrowing costs for issuers. Investment opportunities exist for income-focused investors seeking 4.8% yield exposure to high-quality corporate bonds, though near-term pressure may persist.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
